الفهرس 
Acute lymphoblastic leukemia in older adult patients
Abstract EnglishOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
The outcome of acute lymphoblastic leukemia (ALL) in older adults continue to be poor despite the advances made in the treatment of leukemias. Few studies have included older patients in clinical trial hence very hard to find their characteristic and outcomes. With aging population increasing globally, this challenge should be a concern to all Physicians. We aim in this study to describe the clinicopathological characteristics and treatment outcome of older patients aged >55 years with ALL. Methods: This is a retrospective study that involved all older adult patients with acute lymphoblastic Leukemia diagnosed and treated at the National Cancer Institute Cairo University during the period of January 2011 to June 2020. Results: Overall 59 patients were studied with a median age of 62 years (range 56-81years) with male to female ratio of 1:1.36. Majority of patients (76.3%) presented with poor performance status ({u2161}-{u2163}) and 43.6% with multiple comorbidities.The most common cytogenetic abnormality was Philadelphia chromosome accounting for 47.1%.Complete remission (CR) rate in patients who received curative regimen was 57.1%.with an overall the CR rate of the whole cohort treated with palliative inclusive was 33.9%.The median leukemic free survival was 7.7 months (range 5.1-9.7months) with a cumulative leukemic free survival (LFS) of 64.5%, 29.0%, 29.0% at 6 months 12 months and 36 months respectively.The median Overall survival (OS) was 17 months (range 6.5-28.7months) with an estimated cumulative OS rate of 66.2%, 51.5%, 34.4%% at 6 months 12 months and 36 months respectively